PROKIDNEY CORP.
About PROKIDNEY CORP.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$69.0M
- Total assets
- $335.6M
- Market cap
- $369.4M
- Operating margin
- -18477.8%
- Net margin
- -16977.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $893.0K
- Operating expenses
- $165.9M
- Operating income
- -$165.0M
- Income tax
- $414.0K
- Net income
- -$151.6M
Balance sheet
- Total assets
- $335.6M
- Current assets
- $280.7M
- Total liabilities
- $34.8M
- Current liabilities
- $30.7M
- Shareholders’ equity
- -$1.0B
Cash flow
- Operating cash flow
- -$120.1M
- Investing cash flow
- $104.0M
- Financing cash flow
- $25.6M
- Net cash flow
- $9.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $369.4M
- Shares outstanding
- 216.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 12, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $69.0M.
- Trading 67% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PROKIDNEY CORP..
Write a review
News about PROKIDNEY CORP.
News & sentiment via Polygon.io
